Royal Gabat Lifescience Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 17-11-2024
- Paid Up Capital ₹ 0.10 M
as on 17-11-2024
- Company Age 4 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 7.40%
(FY 2023)
- Profit -342.12%
(FY 2023)
- Ebitda -86.90%
(FY 2023)
- Net Worth -49.37%
(FY 2023)
- Total Assets -9.02%
(FY 2023)
About Royal Gabat Lifescience
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Vijaykumar Kantilal, Vibhuti Shah, and Dhavalkumar Desai serve as directors at the Company.
- CIN/LLPIN
U15400GJ2020PTC116165
- Company No.
116165
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Sep 2020
- Date of AGM
31 Aug 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Royal Gabat Lifescience?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vijaykumar Kantilal  | Director | 04-Sep-2020 | Current |
| Vibhuti Shah | Director | 04-Sep-2020 | Current |
| Dhavalkumar Desai | Director | 18-May-2023 | Current |
Financial Performance of Royal Gabat Lifescience.
Royal Gabat Lifescience Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 7.4% increase. The company also saw a substantial fall in profitability, with a 342.12% decrease in profit. The company's net worth observed a substantial decline by a decrease of 49.37%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Royal Gabat Lifescience?
Unlock access to Royal Gabat Lifescience's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Cosmo Ecosystem Care Private LimitedActive 4 yearsVijaykumar Kantilal and Dhavalkumar Desai are mutual person
- Krushak Mahila Khet Utpadak Producer Company LimitedActive 7 years 11 months
Dhavalkumar Desai is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Royal Gabat Lifescience?
Royal Gabat Lifescience has a workforce of 0 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Royal Gabat Lifescience, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Royal Gabat Lifescience's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
